NTX 565
Alternative Names: NTX-0565; NTX-565Latest Information Update: 22 Nov 2022
At a glance
- Originator Nutcracker Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research T-cell lymphoma
Most Recent Events
- 26 Sep 2022 NTX 0565 is available for licensing as of 26 Sep 2022. https://www.nutcrackerx.com/partnering/
- 26 Sep 2022 Early research in T-cell lymphoma in USA (Parenteral) (Nutcracker Therapeutics pipeline, September 2022)